ArticleACS infectious diseases2018
Inhibition of Acinetobacter-Derived Cephalosporinase: Exploring the Carboxylate Recognition Site Using Novel β-Lactamase Inhibitors.
Open access · greenAbstract read
In one paragraph
Article in ACS infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Chemical Distance-Based Acceleration of Large Library Docking with ChemSTEP.ACS central science · 2026Article
- Discovery of Boronic Acids-Based β-Lactamase Inhibitors Through In Situ Click Chemistry.International journal of molecular sciences · 2025Article
- Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively InhibitsJournal of medicinal chemistry · 2023Article
- Sulfonamidoboronic Acids as "Cross-Class" Inhibitors of an Expanded-Spectrum Class C Cephalosporinase, ADC-33, and a Class D Carbapenemase, OXA-24/40: Strategic Compound Design to Combat Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- Class C β-Lactamases: Molecular Characteristics.Clinical microbiology reviews · 2022Review
- Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors.Scientific reports · 2022Article
- Whole genome sequence of pan drug-resistant clinical isolate of Acinetobacter baumannii ST1890.PloS one · 2022Article
- Phosphorylation of Extracellular Proteins inFrontiers in microbiology · 2021Article
- Structural Insights into Inhibition of the Acinetobacter-Derived Cephalosporinase ADC-7 by Ceftazidime and Its Boronic Acid Transition State Analog.Antimicrobial agents and chemotherapy · 2020Article
- Boronic Acids and Their Derivatives in Medicinal Chemistry: Synthesis and Biological Applications.Molecules (Basel, Switzerland) · 2020Review
- Article
- 1,2,3-Triazolylmethaneboronate: A Structure Activity Relationship Study of a Class of β-Lactamase Inhibitors againstACS infectious diseases · 2020Article
- Structures of FOX-4 Cephamycinase in Complex with Transition-State Analog Inhibitors.Biomolecules · 2020Article
- The β-Lactamase Inhibitor Boronic Acid Derivative SM23 as a New Anti-Frontiers in microbiology · 2020Article
- Heteroaryl Phosphonates as Noncovalent Inhibitors of Both Serine- and Metallocarbapenemases.Journal of medicinal chemistry · 2019Article
- Article
- π-Cation Interactions in Molecular Recognition: Perspectives on Pharmaceuticals and Pesticides.Journal of agricultural and food chemistry · 2018Review
- Exploring Additional Dimensions of Complexity in Inhibitor Design for Serine β-Lactamases: Mechanistic and Intra- and Inter-molecular Chemistry Approaches.Frontiers in microbiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Emilia CaselliDepartment of Life Sciences , University of Modena and Reggio Emilia , Via Campi 101 , 41125 , Modena , Italy.
Chiara RomagnoliDepartment of Life Sciences , University of Modena and Reggio Emilia , Via Campi 101 , 41125 , Modena , Italy.
Rachel A PowersDepartment of Chemistry , Grand Valley State University , 1 Campus Drive , Allendale , Michigan 49401 , United States.ORCID 0000-0002-9968-8284
Magdalena A TaracilaDepartments of Medicine, Pharmacology, Biochemistry and Molecular Biology and Microbiology , Case Western Reserve University , 10900 Euclid Avenue , Cleveland , Ohio 44106 , United States.
Alexandra A BouzaDepartment of Chemistry , Grand Valley State University , 1 Campus Drive , Allendale , Michigan 49401 , United States.
Hollister C SwansonDepartment of Chemistry , Grand Valley State University , 1 Campus Drive , Allendale , Michigan 49401 , United States.
Kali A SmolenDepartment of Chemistry , Grand Valley State University , 1 Campus Drive , Allendale , Michigan 49401 , United States.
Francesco FiniDepartment of Life Sciences , University of Modena and Reggio Emilia , Via Campi 101 , 41125 , Modena , Italy.ORCID 0000-0003-2555-9313
Bradley J WallarDepartment of Chemistry , Grand Valley State University , 1 Campus Drive , Allendale , Michigan 49401 , United States.
Robert A BonomoResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10701 East Boulevard , Cleveland , Ohio 44106 , United States.ORCID 0000-0002-3299-894X
Fabio PratiDepartment of Life Sciences , University of Modena and Reggio Emilia , Via Campi 101 , 41125 , Modena , Italy.
Université Bourgogne Franche-Comté · FRUniversity of Modena and Reggio Emilia · ITCase Western Reserve University · USLouis Stokes Cleveland VA Medical Center · US
Funding
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MSYTEMS AND INTEGRATIVE BIOLOGYT32GM008322 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOW, MALCOLM JAMES · 1990 to 2020
$5.7MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MStructure-based discovery and design of novel class D beta-lactamase inhibitorsR15AI094489 · NIAID · GRAND VALLEY STATE UNIVERSITY · PI POWERS, RACHEL · 2011 to 2014
$709kThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R15 AI094489NIGMS NIH HHS T32 GM008322
Abstract
Boronic acids are attracting a lot of attention as β-lactamase inhibitors, and in particular, compound S02030 ( K
Indexed as
Acinetobacterbeta-Lactamase InhibitorsBinding SitesBoronic AcidsCephalosporinaseCrystallography, X-RayModels, MolecularMolecular StructureProtein BindingProtein Conformationbeta-Lactamase InhibitorsBoronic AcidsCephalosporinaseAcinetobacterboronic acidcarboxylateclick chemistryenzyme plasticitystructure activity relationshipstructure activity relationship studyβ-lactamase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.